Form 4: SOPHIA GENETICS SA: Insider Sells Shares for Tax Withholding

SOPHIA GENETICS SA reports that Chief Scientific Officer Zhenyu Xu sold 7,393 ordinary shares to cover tax obligations related to vested restricted stock units, executed under a Rule 10b5-1 trading plan.

Summary

• Zhenyu Xu, Chief Scientific Officer of SOPHiA GENETICS SA, sold 7,393 ordinary shares on July 6, 2026.
• The sale was conducted to satisfy tax withholding obligations arising from the vesting of restricted stock units on July 2 and July 3, 2026.
• These transactions were executed under a pre-established Rule 10b5-1(c) trading plan, indicating they were not discretionary.
• The shares were sold at a weighted average price of $5.1727, with individual sales ranging from $4.97 to $5.43.
• Following the sale, Zhenyu Xu beneficially owns 614,887 ordinary shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the share sale is a routine transaction for tax purposes under a pre-arranged plan, rather than an indicator of management's confidence in the company's future performance.

Positives

• The sale was conducted under a Rule 10b5-1(c) trading plan, which is designed to comply with insider trading regulations and provides an affirmative defense against allegations of insider trading.
• The transaction was solely to cover tax withholding obligations, suggesting it was a necessary administrative action rather than a reflection of negative sentiment towards the company's stock.
• The reporting person retains a significant beneficial ownership of 614,887 ordinary shares, indicating continued substantial investment in the company.

Negatives

• A sale of company shares by a key executive, even if for tax purposes, can sometimes be perceived negatively by the market.
• The sale represents a reduction in the reporting person's direct shareholding, albeit for a specific, non-discretionary reason.

Risks

• Potential for negative market perception of insider share sales, regardless of the stated reason.
• The Rule 10b5-1(c) plan itself could be subject to scrutiny if not properly structured or executed.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it solely reports on a past transaction.

Management Comments

• Sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades.
• The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1(c) plan by SOPHiA GENETICS SA's Chief Scientific Officer is a common practice for executives to manage their stock holdings and comply with regulations while diversifying or meeting financial obligations.

Stakeholder Impact

• Shareholders: May interpret the sale as a reduction in insider ownership, though the tax-related nature and Rule 10b5-1(c) plan mitigate significant concern.
• Employees: The transaction is related to executive compensation and does not directly impact other employees.
• Management: Demonstrates adherence to regulatory requirements for insider transactions.

Next Steps

• The reporting person may continue to execute trades under the Rule 10b5-1(c) plan if it remains active.
• The company may receive requests for detailed pricing information regarding the sales.

Key Dates

Keywords

SOPHIA GENETICS SA, SOPH, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Tax Withholding, Restricted Stock Units, Beneficial Ownership, Executive Compensation